|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,990.50 INR | -0.53% |
|
+2.54% | +15.75% |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 | |
| 07-31 | Sun Pharmaceutical's Consolidated Net Profit Grows in Fiscal Q1 | MT |
| Market Cap | 4,776B 50.03B 43.49B 40.48B 37.17B 70.19B 71.27B 477B 187B 2,378B 188B 184B 7,973B | P/E 2027 * |
36.4x | P/E 2028 * | 30.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,470B 46.82B 40.7B 37.89B 34.78B 65.69B 66.71B 447B 175B 2,225B 176B 172B 7,462B | EV / Sales 2027 * |
6.89x | EV / Sales 2028 * | 6.07x |
| Free-Float |
44.39% | Yield 2027 * |
0.86% | Yield 2028 * | 0.89% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.53% | ||
| 1 week | +2.54% | ||
| 1 month | +6.87% | ||
| 3 months | +10.08% | ||
| 6 months | +24.77% | ||
| Current year | +15.75% |
| 1 week | 1,933 |  | 2,046.9 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 2025-08-31 | |
| Director/Board Member | 73 | 2018-05-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.53% | +2.54% | +16.63% | +74.09% | 50.03B | |
| -1.81% | -0.49% | +48.83% | +107.71% | 36.6B | |
| +0.46% | +4.44% | -5.24% | +25.38% | 12.47B | |
| +1.05% | +1.63% | +16.19% | +78.22% | 11.77B | |
| -1.33% | -0.76% | +30.08% | +131.70% | 9.04B | |
| -2.99% | -2.09% | +45.28% | -11.87% | 7.03B | |
| +0.51% | +1.46% | +12.17% | +32.88% | 6.79B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +1.99% | +1.91% | +4.68% | +183.54% | 6.6B | |
| -.--% | -1.95% | - | - | 5.73B | |
| Average | -0.26% | +0.53% | +21.08% | +77.71% | 15.28B | |
| Weighted average by Cap. | -0.60% | +0.78% | +24.57% | +81.44% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 649B 6.8B 5.91B 5.5B 5.05B 9.54B 9.69B 64.86B 25.46B 323B 25.54B 24.98B 1,084B | 731B 7.65B 6.65B 6.19B 5.68B 10.74B 10.9B 72.99B 28.65B 364B 28.74B 28.11B 1,219B |
| Net income | 136B 1.42B 1.24B 1.15B 1.06B 1.99B 2.02B 13.56B 5.32B 67.55B 5.34B 5.22B 226B | 156B 1.64B 1.42B 1.32B 1.22B 2.3B 2.33B 15.61B 6.13B 77.78B 6.15B 6.01B 261B |
| Net Debt | -306B -3.21B -2.79B -2.59B -2.38B -4.5B -4.57B -30.58B -12B -152B -12.04B -11.78B -511B | -341B -3.57B -3.1B -2.89B -2.65B -5.01B -5.09B -34.07B -13.37B -170B -13.41B -13.12B -569B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-31 | ₹1,990.50 | -0.53% | 4,954,449 |
| 26-07-30 | ₹2,001.10 | +0.56% | 2,224,264 |
| 26-07-29 | ₹1,989.90 | +0.67% | 2,682,295 |
| 26-07-28 | ₹1,976.70 | +0.15% | 4,579,529 |
| 26-07-27 | ₹1,973.70 | +1.68% | 5,414,380 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
